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Abstract
Background
Population-based, prospective studies can provide important insights into Parkinson’s dis-
ease (PD) and other parkinsonian disorders. Participant follow-up in such studies is often
achieved through linkage to routinely collected healthcare datasets. We systematically
reviewed the published literature on the accuracy of these datasets for this purpose.
Methods
We searched four electronic databases for published studies that compared PD and parkin-
sonism cases identified using routinely collected data to a reference standard. We extracted
study characteristics and two accuracy measures: positive predictive value (PPV) and/or
sensitivity.
Results
We identified 18 articles, resulting in 27 measures of PPV and 14 of sensitivity. For PD, PPV
ranged from 56–90% in hospital datasets, 53–87% in prescription datasets, 81–90% in pri-
mary care datasets and was 67% in mortality datasets. Combining diagnostic and medication
codes increased PPV. For parkinsonism, PPV ranged from 36–88% in hospital datasets, 40–
74% in prescription datasets, and was 94% in mortality datasets. Sensitivity ranged from 15–
73% in single datasets for PD and 43–63% in single datasets for parkinsonism.
Conclusions
In many settings, routinely collected datasets generate good PPVs and reasonable sensitivi-
ties for identifying PD and parkinsonism cases. However, given the wide range of identified
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Introduction
Despite well-established pathological features, the aetiologies of Parkinson’s Disease (PD) and
other parkinsonian conditions remain poorly understood and disease-modifying treatments
have proved elusive[1]. Large, prospective, population-based cohort studies with biosample
collections (e.g., UK Biobank, German National Cohort, US Precision Medicine Initiative)
provide a robust methodological framework with statistical power to investigate the complex
interplay between genetic, environmental and lifestyle factors in the aetiology and natural his-
tory of neurological disorders such as PD and other parkinsonian disorders[2–4].
Linkage to routinely collected healthcare data–which are administrative datasets collected
primarily for healthcare purposes rather than to address specific research questions[5]–pro-
vides an efficient means of long term follow-up in order to identify large numbers of incident
cases in such studies[2]. Furthermore, participant linkage to such datasets can be used in ran-
domised controlled trials as a cost-effective and comprehensive method of follow-up for dis-
ease outcomes[6]. These data are coded using systems such as the International Classification
of Diseases (ICD)[7], the Systematized Nomenclature of Medicine–Clinical Terms (SNO-
MED-CT) system[8], and the UK primary care Read system[9].
There are several mechanisms by which inaccuracies can arise when using routinely col-
lected healthcare data to identify PD outcomes. False positives (participants who receive a dis-
ease code but do not have the disorder) may arise if a clinician incorrectly diagnoses the
condition. Given that PD and other parkinsonian disorders are largely clinical diagnoses made
without a definitive diagnostic test, there is the potential for diagnostic inaccuracies. Clinico-
pathological studies have shown discrepancies between clinical diagnoses in life and neuro-
pathological confirmation[10] and there is evidence that accuracy increases when diagnoses
are made by movement disorder specialists[11–13]. Secondly, diagnoses may be incorrectly
recorded in medical records, or errors may arise during the coding process. Similarly, false
negatives (patients who have the condition but do not receive a code) may arise due to under-
diagnosis, omission of the diagnosis from the medical records (e.g., because the condition is
not the primary reason for hospital admission), or errors during the coding process.
As a result, before such datasets can be used to identify PD and parkinsonism cases in pro-
spective studies, their accuracy must be determined. Important measures are the positive pre-
dictive value (PPV, the proportion of those coded positive that are true disease cases) and
sensitivity (the proportion of true disease cases that are coded positive). Specificity and nega-
tive predictive value are less relevant metrics in this setting. A high specificity (the proportion
of those without the disease that do not receive a disease code) is important to ensure a high
PPV, thereby minimising bias in effect estimates. With an appropriately precise choice of
codes, the specificity of routinely collected healthcare data to identify disease cases in popula-
tion-based studies is usually very high (98–100%)[14,15]. However, in a population-based
cohort study where the overall prevalence of a disease is low, a high specificity does not guar-
antee a high PPV—a large absolute number of people without the disease can be incorrectly
classified as being disease cases (false positives), yet the overall proportion of misclassified
cases can be low (high specificity, low PPV)[16]. NPV, like PPV, is related to disease
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prevalence and will therefore be high in population-based studies where most individuals do
not develop the disease of interest[14].
Previous systematic reviews on the accuracy of routine data to identify other neurological
diseases such as stroke[14], dementia[17] and motor neurone disease[18] have summarised
the existing literature and identified methods by which accuracy can be improved, as well as
areas for further evaluation. Here, we systematically reviewed published studies that evaluated
the accuracy of routinely collected healthcare data for identifying PD and parkinsonism cases.
Methods
Study reporting
We followed the Preferred Reporting Items for Systematic Review and Meta-analysis state-
ment (PRISMA) guidelines for the reporting of this systematic review[19].
Study protocol
We used the PRISMA Protocols (PRISMA-P) guideline to aid in the design of this study[20],
and prospectively published the protocol (number: CRD42016033715, www.crd.york.ac.uk/
PROSPERO/display_record.php?ID = CRD42016033715) [21].
Search strategy
We (AS & TW) searched the electronic databases MEDLINE (Ovid), EMBASE (Ovid), CEN-
TRAL (Cochrane Library) and Web of Science (Thomson Reuters) for relevant articles pub-
lished in any language between 01.01.1990 and 23.06.2017. Our search strategy is outlined in
S1 File. We chose the date limits based on our judgement that accuracy estimates from studies
published prior to 1990 would have limited current applicability. We did not exclude studies
based on the dates covered by the datasets. We also screened bibliographies of included studies
and relevant review papers to identify additional publications.
Eligibility criteria
To be included, studies had to have: compared codes for PD or parkinsonism from routinely
collected healthcare data to a clinical expert-derived reference standard, and provide either a
PPV and/or a sensitivity estimate (or sufficient raw data to calculate these). We excluded stud-
ies with<10 coded cases, due to the limited precision of studies below this size[17,18]. Studies
reporting sensitivity values had to be population-based (i.e. community-based as opposed to
hospital-based) with comprehensive attempts to detect all disease cases. Where multiple stud-
ies investigated overlapping populations, we included the study with the larger population size.
Where articles assessed more than one dataset or evaluated both PPV and sensitivity, we
included these as separate studies. Hereafter, we will refer to published papers as ‘articles’ and
these separate analyses as ‘studies’.
Study selection
Two authors (AS and SH) independently screened all titles and abstracts generated by the
search, and reviewed full text articles of all potentially eligible studies to determine if the inclu-
sion criteria were met. In the case of disagreement or uncertainty, we reached a consensus
through discussion and, where necessary, involvement of a senior third author (CLMS).
Parkinson’s disease and parkinsonism in routine health data
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Data extraction
Using a standardized form, two authors (TW and ZH) independently extracted the following
data from each study: first author; year of publication; time period during which coded data
were collected; country of study; study population; average age of disease cases (or, if this was
unavailable, the ages of participants at recruitment); study size (defined as the total number of
code positive cases for PPV [true positives plus false positives] and the total number of true
positives for sensitivity [true positives and false negatives]); type of routine data used (e.g., hos-
pital admissions, mortality or primary care); coding system and version used; specific codes
used to identify cases; diagnostic coding position (e.g. primary or secondary position); parkin-
sonian subtypes investigated; and the method used to make the reference standard diagnosis.
We recorded the reported PPV and/or sensitivity estimates, as well as any corresponding
raw data. After discussion, any remaining queries were resolved with a senior third author
(CLMS). When necessary, we contacted study authors to request additional information.
Quality assessment
We adapted the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2)[22] tool
to evaluate the risk of bias in the estimates of accuracy and any concerns about the applicability
of each article to our specific research question (S2 File). Two authors (TW and ZH) indepen-
dently assigned quality ratings, with any discrepancies resolved through discussion. We per-
formed this evaluation in the context of our specific review question and not as an indication
of the overall quality of the articles. We assessed risk of bias at the article level rather than
study level, as the methods for each study within an article were very similar. We did not
exclude studies based on their quality assessment ratings, but rather considered a given study’s
results in the context of the article’s risk of bias and applicability concerns. Where articles
deemed to be at low of bias and articles at high risk of bias reported PPV or sensitivity esti-
mates on the same type of dataset, we compared the reported estimates to assess the potential
effect of bias on accuracy estimates.
Statistical analysis/data synthesis
We tabulated the extracted data, and calculated 95% confidence intervals for the accuracy mea-
sures from the raw data using the Clopper-Pearson (exact) method. Due to substantial hetero-
geneity in study settings and methodologies, we did not perform a meta-analysis, as we
considered any summary estimate to be potentially misleading. Instead, we assessed the full
range of results in the context of study methodologies, populations and specific data sources.
We also reported any within-study comparisons in which a single variable was changed to
examine its effect on PPV or sensitivity. We performed analyses using the statistical software
StatsDirect3.
Results
Study characteristics
From an initial 1319 identified articles, we removed 222 duplicates and excluded 994 consid-
ered to be irrelevant after screening the titles and abstracts. We therefore examined the full
text articles for 103 papers. Of these, we excluded 37 that did not assess the accuracy of a rou-
tinely collected, coded dataset, 21 that did not validate the coded data against any reference
standard, 12 that were not primary research studies, 11 that combined routine and non-rou-
tine data, three where no accuracy measure was reported or calculable, and four that did not
assess coding in PD. 18 published articles fulfilled our inclusion criteria[23–40]. A flow
Parkinson’s disease and parkinsonism in routine health data
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diagram of the study selection process is shown in Fig 1. We obtained key additional informa-
tion from the authors of two studies[32,36]. Of the 18 included articles, 13 reported PPV
[23,25–36], four reported sensitivity[37–40] and one reported both[24]. Four articles con-
tained more than one study[23–25,29]. One of these consisted of multiple sub-studies, using
different methods to evaluate datasets across several countries, so we included these as six sep-
arate studies[25]. In total, there were 27 measures of PPV and 14 of sensitivity. Study charac-
teristics are summarised in Tables 1 and 2 respectively.
Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pone.0198736.g001
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Study size varied considerably, ranging from 39–4957. All 18 articles were based in high-
income countries. Three were from the UK[32,33,40], six from mainland Europe[24,25,30,37–
Table 2. Characteristics of studies reporting sensitivity, stratified by dataset type.
First
author,
year of
publication
Year
of
study
Country Study population
composition
Age
(years)�
Proportion
male
Study size (n) Routine
dataset
used
Coding
system
Codes used to
identify cases
Diagnostic
coding
position
Reference
standard
Mortality certificate-derived datasets:
Benito-
Leόn
2014[37]
1994–
2007
Spain Three
communities
near Madrid
Mean
77
56% 82 Mortality ICD-9
(pre
1999)
ICD-10
(post
1999)
Not specified
(investigated
PD)
Primary Screening (in-
person,
telephone and
mail
questionnaire)
and
neurological
examination
Beyer
2001[38]
1993–
1996
Norway County
(Rogaland)
Mean
79
Unclear 84 Mortality ICD-9
or ICPC
Not specified
(investigated
PD)
Primary
+ Any
Semi-structured
interview and a
clinical
examination
Fall
2003[39]
1989–
1998
Sweden Central district of
Ӧstergӧtland
Mean
82
Unclear 121 Mortality ICD-9 Not specified
(investigated
PD)
Primary
+ Any
Examination
and medical
record review
Feldman
2012[24]
1998–
2008
Sweden Twins across
Sweden >50yrs
Mean
75
Unclear PD: 77
Parkinsonism:
127
Mortality ICD-10 PD: G20
Parkinsonism:
G21.4, G21.8,
G21.9, G23.1,
G23.2, G23.9,
G25.9
Any Screening
interview,
medical record
review and
examination
Williams-
Gray
2013[40]
2000–
2012
UK County
(Cambridgeshire)
Mean
70
Unclear 63 Mortality Not
specified
Not specified
(investigated
PD)
Primary
+ Any
History and
neurological
examination
Hospital-derived datasets:
Feldman
2012[24]
1964–
2009
Sweden Twins across
Sweden >50yrs
Mean
75
Unclear PD: 132
Parkinsonism:
194
Hospital:
inpatient
ICD-7
(1961–
67)
ICD-8
(1968–
86)
ICD-9
(1987–
96)
ICD-10
(1997–
2009)
PD: ICD-7:
350; ICD-8:
342.00; ICD-9:
332.0; ICD-10:
G20
Parkinsonism:
ICD-8: 342.08,
342.09; ICD-9:
333.0;
ICD-10: G21.4,
G21.8, G21.9,
G23.1, G23.2,
G23.9, G25.9
Any Screening
interview,
medical record
review and
examination
Year of study: the time period during which coded data was collected.
�—any information given regarding the ages of cases or age at recruitment Study size: the total number of true positive according to the reference standard (true
positives and false negatives). Where both PD and parkinsonism were investigated in one article, study sizes for both are displayed. Study population composition:
population cohort from which cases were identified.
ICD codes for Parkinson’s disease—ICD-7 350; ICD-8 342.00; ICD-9 332.0; ICD-10 G20.
ICD codes for other Parkinsonism—ICD-8: 342.08 (other defined Parkinsonism), 342.09 (unspecified Parkinsonism); ICD-9: 333.0 (other degenerative diseases of the
basal ganglia); ICD-10: G21.4 (vascular Parkinsonism), G21.8 (other defined secondary Parkinsonism), G21.9 (unspecified secondary Parkinsonism), G23.1 (progressive
supranuclear ophthalmoplegia), G23.2 (striatonigral degeneration), G23.9 (unspecified degenerative disease of basal ganglia), G25.9 (unspecified extrapyramidal and
movement disorder).
https://doi.org/10.1371/journal.pone.0198736.t002
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Fig 2. Positive predictive values (PPVs) of coded diagnoses. Study size: total number of code-positive cases (true positives + false positives). �Exact
sample size unknown, most conservative estimate used. Box sizes reflect Mantel-Haenszel weight of study (inverse variance, fixed effects).
https://doi.org/10.1371/journal.pone.0198736.g002
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39], eight from the USA[26–29,31,34–36], and one from Canada[23]. There were 12 PPV esti-
mates and two sensitivity estimates from hospital data[23–31], two PPV and 10 sensitivity esti-
mates from mortality data[24,37–40], two PPV estimates from primary care data[32], four
PPV estimates from prescription data[23,29,33] and seven PPV estimates and two sensitivity
estimates from combining datasets from different sources[24,25,34–36]. There were no sensi-
tivity estimates from primary care or prescription data.
PD was evaluated in 13 articles, with eight estimating PPV[25,26,28–30,32,33,36], four esti-
mating sensitivity[37–40] and one estimating both[24]. Parkinsonism was evaluated by seven
articles, of which six estimated PPV[23,27,31,33–35] and one assessed both PPV and sensitiv-
ity[24]. All of the parkinsonism articles combined PD with other causes of parkinsonism.
The methods of reference standard used could be broadly divided into two categories:
patient history and examination (5/5 articles reporting sensitivity) and medical record review
(14/14 of articles reporting PPV). Three articles used in-person examination and medical
record review in combination[24,33,39]. In addition, where entire populations were under
Table 3. Within-study analyses. Algorithm development.
Criteria applied: PPV % (95% CI) Number of cases
identified
Parkinson’s Disease
a) Feldman 2012 (hospital inpatient data)
Parkinson’s disease ICD code only 71 (59–81) 72
Exclusion of patients with other (non-Parkinson’s disease)
parkinsonian codes
70 (58–81) 67
Code frequency�2 hospital admissions 76 (61–88) 42
Code in primary diagnostic position 83 (70–92) 53
Code assigned in specialist department (neurological/
neurosurgical/geriatric)
83(63–95) 24
b) Szumski 2009 (hospital outpatient data)
Parkinson’s disease ICD codes only 76 (72–79) 579
Code frequency�2 at any clinic 79(76–83) 409
Code assigned in any neurology clinic 79 (75–83) 352
Code assigned in movement disorder speciality clinic 87 (81–92) 177
Code + prescribed antiparkinsonian medication 86 (82–89) 408
c) Wei 2016
Parkinson’s disease ICD codes only 89 (81–94) 100
Prescription only 87 (78–93) 100
ICD code and prescription 94� Unknown�
Parkinsonism
d) Butt 2014
Hospital inpatient ICD code ever 87 (79–96) 63
Hospital outpatient ICD code ever 55 (49–60) 297
Prescription ever 40 (35–44) 395
Outpatient code frequency�2 in one year 83 (77–89) 169
Outpatient code frequency�2 in one year by a specialist 87 (81–92) 134
Outpatient code AND Prescription 85 (79–90) 174
Prescription AND outpatient code within +/- 6 months 87 (82–92) 166
The effect of additional criteria to identify PD cases on PPV and the number of cases identified.
� Sample size and confidence intervals unknown for this accuracy measure.
https://doi.org/10.1371/journal.pone.0198736.t003
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study, some studies incorporated a screening method (e.g., telephone interview) to identify
potential cases[24,37].
Where reported, codes used to identify PD cases were consistent and appropriate to the
ICD version used. However, the range of codes used to identify other parkinsonian conditions
varied considerably, reflecting the broad range of pathologies that can lead to parkinsonism.
Seven studies did not specify the exact codes used[29,32,33,37–40]. ICD versions used reflected
the time period over which the studies were conducted. 19 studies used ICD-9 (or ICD-9-CM,
a clinically modified version used in the USA, and identical to ICD-9 with respect to parkinso-
nian diagnoses)[23–29,31,35–39], 11 used ICD-10[23–25,30,37], three used ICD-8[24,30], and
two used ICD-7[24]. One of the primary care studies used Read-coded data[32]. Four studies,
including the three that evaluated prescription data, did not specify the coding system used
[23,29,33,40].
The diagnostic coding position assessed also varied. Three studies assessed primary diagno-
ses alone[30,36,37], eight used any diagnostic position[24,31,38–40], while 13 did not specify
the coding position[23,25–29,34,35]. Diagnostic position was not applicable in the studies of
primary care and prescription data due to the nature of these datasets[23,29,32,33].
Quality assessment
Only two articles were judged to be of low risk of bias or applicability concerns in the QUA-
DAS-2 assessment[23,24] (S1 Table). Across the risk of bias domains, the most common area
of concern was inappropriate or unclear code lists to identify disease cases (10/18), followed
by: selection bias (8/18), patient flow (i.e. inappropriate inclusions and exclusions or patients
being lost to follow-up) (5/18) and insufficiently rigorous or unclear reference standards (4/
18).
Positive predictive value
For PD, there were 17 PPV estimates in total (Fig 2)[24–26,28–30,32,33,36]. These comprised
seven PPV estimates of hospital data alone[24–26,28–30], one of mortality data alone[24], two
for prescription data alone[29,33], one of primary care data alone[32], one of prescription data
and primary care data in combination[32], and five of datasets used in combination[25,36].
PPVs ranged from 36–90% across all studies. Nine of the 17 estimates were>75%. The single
study of Read coding in primary care data alone reported a PPV of 81%, increasing to 90%
with the presence of a relevant medication code in addition to a diagnostic code[32]. The two
studies of medication data alone reported PPVs of 53% and 87%[29,33]. The single, small
study of mortality data had a PPV of 67%[24].
One of the two articles judged to be at low risk of bias investigated the PPV of hospital
admissions data to identify PD, reporting a PPV of 70.8%[24]. This value fell in between the
range of other studies (range 55.5–90.3%), raising the possibility that estimates from studies at
the extremes of the range may be influenced by bias.
Several within-study comparisons were available from three studies identifying PD
(Table 3)[24,28,29]. Two of these investigated the change in PPV for hospital data to identify
PD when algorithms containing additional criteria were used[24,28]. Both showed a moderate
increase in PPV if a relevant diagnosis code was recorded more than once, or if a specialist
department assigned such a code. One study reported an increase in PPV when only primary
position diagnoses were assessed[24]. Another showed that incorporating selected medication
codes with diagnosis codes increased the PPV from 76% to 86%, although this was at the
expense of reduced case ascertainment[28]. Finally, one study showed that the combination of
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a diagnostic code in hospital data with a relevant medication code increased the PPV when
compared to using either dataset alone (94% versus 87% and 89% respectively)[29].
For parkinsonism, there were 10 PPV estimates in total (Fig 2)[23,24,27,31,33–35]. These
comprised five estimates from hospital data alone[23,24,27,31], two from prescription data
alone[23,33], one from mortality data alone[24], and two from using datasets in combination
Fig 3. Sensitivity estimates of coded diagnoses. Study size: total number of true positives according to reference standard (true positives + false negatives). �Unknown
sample size and confidence intervals. Box sizes reflect Mantel-Haenszel weight of study (inverse variance, fixed effects).
https://doi.org/10.1371/journal.pone.0198736.g003
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[34,35]. PPVs ranged from 40–94% in the single datasets and from 22–28% in the combination
datasets. The two studies of parkinsonism in prescription data produced very different PPV
estimates of 40% and 74%[23,33]. One of these studies reported that the PPV of medication
data to identify any parkinsonian disorder was considerably higher than that for PD (74% and
53% respectively)[33].
The two articles with low risk of bias investigated the use of hospital admissions data to
identify parkinsonism cases. These articles reported PPVs of 76%[23] and 88%[24], which is
consistent with the values reported by other studies judged to be at risk of bias.
Sensitivity
For PD, there were 11 sensitivity estimates in total (Fig 3)[24,37–40]. Of these, nine were sensi-
tivity estimates for mortality data alone, consistently showing that codes in the primary posi-
tion only gave low sensitivities of 11–23%, rising to 53–60% when codes from any position
were included[24,37–40]. A single study reported the sensitivity of hospital data to be 73%,
increasing to 83% when hospital and mortality data were combined. There were no sensitivity
estimates for primary care or prescription data.
Of the two studies with low risk of bias, one investigated the sensitivity of mortality data,
reporting a value of 20%. This was similar to the values reported by other studies deemed at
risk of bias, suggesting that the potential bias identified did not significantly affect these
estimates.
For parkinsonism, there were three sensitivity estimates, all from one study[24]. Hospital
admissions and mortality data combined gave higher sensitivity (71%) compared with either
mortality or hospital data alone (43% and 63% respectively).
Discussion
We have demonstrated that existing validation studies show a wide variation in the accuracy
of routinely collected healthcare data for the identification of PD and parkinsonism cases.
Despite this, in some circumstances, achieving high PPVs is possible. Sensitivity (range 15–
73% for PD) is generally lower than PPV (range 36–90%) in single datasets, but is increased by
combining data sources.
When using routinely collected datasets to identify disease cases, there will inevitably be a
trade-off between PPV and sensitivity[16]. The extent to which cohorts seek to maximise one
accuracy metric over another will depend on the specific study setting and research question.
For example, for studies that rely only on routinely collected data to identify disease cases are
likely to desire a high PPV, providing sensitivity is sufficient to ensure statistical power in anal-
yses. In contrast, for studies that use routinely collected data to identify potential cases before
going onto validate these cases with a more detailed in-person or medical record review, a
high sensitivity will be important. In this review, we found that the sensitivity of mortality data
to detect PD using codes in the primary position alone was very low (range 11–23%) however,
this markedly improved (range 56–60%) when codes were selected from any position on the
death certificate[24,37–40]. No studies in this review investigated the effect of coding position
on PPV, but previous studies of dementia and motor neurone disease have shown that select-
ing cases for whom the disease code was in the primary position consistently led to increased
PPVs compared to selecting disease codes from any position[41–44]. However, as with PD,
this approach led to the identification of fewer cases, thereby reducing sensitivity[17,18].
The pharmacological treatment of PD is largely focussed on improving motor function and
patients are treated with a limited number of drugs. This has allowed antiparkinsonian drugs
to be used as ‘tracers’ in epidemiological studies[45,46]. There are potential problems with
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using prescription data as a proxy for PD diagnosis. This approach may disproportionately
under-identify patients with early stage disease who do not yet require treatment. Also, a
response to a trial of dopaminergic drugs may be used as part of the diagnostic assessment in
potential PD cases, meaning some patients prescribed antiparkinsonian medications will not
be subsequently diagnosed with PD. Furthermore, antiparkinsonian can be prescribed for
indications other than PD (such as dopamine agonists for restless legs syndrome, endocrine
disorders and other forms of parkinsonism). The specific drugs licensed for use in parkinso-
nian conditions varies between countries and may change over time. Therefore, an algorithm
incorporating prescription data would need to be continually revised to match prescribing pat-
terns. Results from our review suggest that prescription data alone has a low PPV for PD case
ascertainment[33]; however, when drug codes are combined with diagnostic codes, PPV
increases but with reduced case ascertainment[28,32]. Furthermore, prescription datasets
appear to have a higher PPV when identifying any parkinsonian disorder rather than specifi-
cally PD[33].
This study has several strengths and limitations. Our review benefits from prospective pro-
tocol publication, comprehensive search criteria, and independent duplication of each stage by
two authors. Despite this, relevant studies may still have been missed, especially if a validation
study was a subsection of a paper with a wider aim. As all eligible studies were included, the
results may have been influenced by studies of lower quality. Only two articles were found to
be at low risk of bias or applicability concerns[23,24], and it is likely that biases in study design
would have affected the results. For example, one study with the lowest PPV[35] used very
broad ICD-9 codes such as 781.0 (abnormal involuntary movements) and 781.3 (lack of
coordination).
Since there is no method of diagnosing PD with certainty in life, there is likely to be some
misclassification of the reference standards used in the studies. The application of stringent
diagnostic criteria to reference standard diagnoses, although often necessary for research pur-
poses, may lead to some patients being misclassified as ‘false positives’ when they do in fact
have the condition. This may lead to underestimation of the PPV in some of the studies. When
considering the ideal reference standard for validation studies, there is a trade-off between the
robustness of the reference standard and validating sufficient cases to produce precise accuracy
estimates. For example, in-person neurological examination may have greater diagnostic cer-
tainty than medical record review but this becomes difficult as the cohort size increases. Some
of the variation in the reported results, therefore, is likely to be due to differences in how strin-
gently different studies applied their reference standards.
Many of the studies reported cases with insufficient information to meet the reference stan-
dard and the handling of these varied. Some studies excluded such cases, others classified them
as false positives, while some did not specify how they handled such missing data. Excluding
such cases may introduce selection bias, whereas counting them as false positives may underes-
timate PPV.
The effect of possible publication bias on the results is difficult to estimate, but dispropor-
tionate publication of studies which report more favourable accuracy measures may lead to
over-estimation of the performance of the codes. In addition, estimates of PPV are dependent
upon the prevalence of the condition in the study population but it was not possible to assess
the prevalence of PD within each study population.
Our review highlights several areas requiring further research. Given that the management
of PD is largely delivered in outpatients or the community, primary care data may be an effec-
tive method of identifying cases. Whilst studies have suggested that PD diagnoses made in pri-
mary care are less accurate than those made in a specialist setting[47,48], primary care records
combine notes made by primary care clinicians with prescription records and correspondence
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from secondary care. Codes from primary care should therefore include diagnoses made by
specialists, thus increasing their accuracy. We found only one small study of primary care
data, reporting a promising PPV of 81%, improving to 90% with the inclusion of medication
codes[32]. No studies investigated the sensitivity of primary care data. Further research into
the accuracy of primary care data is needed.
Two studies investigated using algorithmic combinations of codes from different sources to
improve PPV[24,28]. These investigated the additional benefit of the inclusion of factors such
as only including codes that appeared more than once, selecting codes in the primary position
only, combining diagnostic codes with prescription data, and only including diagnoses made
in specialist clinics. These methods increased PPV but at a cost to the number of cases identi-
fied. The development of algorithms that maximize PPV whilst maintaining a reasonable sen-
sitivity (e.g., by combining multiple complimentary datasets) merits further evaluation.
To our knowledge, no studies have evaluated the accuracy of routinely collected healthcare
data for solely identifying atypical parkinsonian syndromes such as PSP and MSA. Further
work is needed to understand whether these datasets provide a valuable resource for studying
these less common diseases.
In conclusion, our review summarises existing knowledge of the accuracy of routinely col-
lected healthcare data for identifying PD and parkinsonism, and highlights approaches to
increase accuracy and areas where further research is required. Given the wide range of
observed results, prospective cohorts should perform their own validation studies where evi-
dence is lacking for their specific setting.
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